High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

Samar K. Darweesh,Kadry Elsaeed,Heba Omar,Maissa El Raziky,Wafaa El Akel,Magdy El-Serafy,Sohier Ahmed Ismail,Ahmed A. Gomaa,Mai Mehrez,Mahamed El Kassas,Mohamed Abdullah,Mohammed Shaker,Gamal Esmat,Yehia El-Shazly,Wahid Doss,Imam Waked

High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless of RAS testing: A real-life multicenter study

2019

Samar K. Darweesh
Kadry Elsaeed
Heba Omar
Maissa El Raziky
Wafaa El Akel
Magdy El-Serafy
Sohier Ahmed Ismail
Ahmed A. Gomaa
Mai Mehrez
Mahamed El Kassas
Mohamed Abdullah
Mohammed Shaker
Gamal Esmat
Yehia El-Shazly
Wahid Doss
Imam Waked

ABSTRACTAim: Evaluation of the efficacy and safety of sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV) in treating non-sustained virological responders (non-SVR12) to prior sofosbuvir-based therapy, ...

Keywords:

Pathology
Sofosbuvir
Diabetes mellitus
Oncology
Internal medicine
Medicine
Ribavirin
virologic response
multicenter study
anti hiv
Daclatasvir

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations